Cipher Pharmaceuticals Stock (OTC: CPHRF)

Cipher Pharmaceuticals (OTC:CPHRF) Stock, Quote.Headers.trade-ideas

Cipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, specialty medicines, and Out-Licensed Products among others. The company's geographical operational areas include Canada and the United States.

Cannabis

After-Hours Center

Markets

Movers

Trading Ideas

LVCNF

SEED

ICNAF

SNDL

CPHRF

NINE

CNPOF

ARNA

AUSAF

NXGWF

ALEAF

CNTMF

CWBHF

CURR

CNVCF

CVSI

TLRY

CRBP

XXII

UGRO

YCBD

TBPMF

BMMJ

GNLN

CXXIF

TGODF

GRWG

CRLBF

GTBIF

CANN

CNBX

GAINERS:


	Leviathan Natural Prods (OTC:LVCNF) shares closed up 14.86% at $0.52 with an estimated market cap of $43.9M.


Marijuana Stock Movers For October 8, 2021

News

NDVAF

RHNMF

HEXO

TCNNF

TRSSF

MBII

ZYNE

CBWTF

GENE

BLOZF

GAINERS:


	Tetra Bio Pharma (OTC:TBPMF) shares closed up 21.96% at $0.22 with an estimated market cap of $88.1M.


Top Cannabis Movers For October 5, 2021

WRLD

INLB

NWVCF

EPWCF

HRVSF

MMNFF

GAINERS:


	Mexco Energy (AMEX:MXC) shares closed up 12.88% at $11.74 with an estimated market cap of $24.6M.


Aurora &amp; Trulieve Among Top Cannabis Movers For Oct 1, 2021 - Full Canna Movers Index

CIPHER PHARMS INC ORD by Cipher Pharmaceuticals, Inc.

Cipher Pharmaceuticals Inc

Post Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POST#NYSE">POST</a>) (the "Company" or "Post") today announced it intends to commence a private offering to eligible purchasers, subject to market and other conditions, of $500.0 million in aggregate principal amount of senior notes due 2034 (the "Notes"). The Notes will be unsecured, senior obligations of the Company and will be guaranteed by the Company's existing and subsequently acquired or organized domestic subsidiaries (other than immaterial subsidiaries, certain excluded subsidiaries and subsidiaries designated as unrestricted subsidiaries).
The Company intends to use the net proceeds from the Notes offering to pay the costs, fees and expenses associated with the Notes offering and to redeem all of the Company's outstanding 5.625% senior notes due 2028, including payment of any premiums, fees, costs and expenses associated therewith. To the extent there are any remaining net proceeds, the Company intends to use such proceeds for general corporate purposes, which could include, among other things, acquisitions, share repurchases, retirement or repayment of existing debt, capital expenditures and working capital. The final terms and amounts of the Notes are subject to market and other conditions and may be materially different than expectations. The offering is not conditioned upon the consummation of the redemption of the Company's 5.625% senior notes due 2028, which is expected to occur on or after December 1, 2024.

Offerings

POST

Post Holdings Intends To Commence A Private Offering To Eligible Purchasers $500M In Aggregate Principal Amount Of Senior Notes Due 2034

Post Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POST#NYSE">POST</a>), a consumer packaged goods holding company, today affirmed its non-GAAP Adjusted EBITDA guidance for fiscal year 2024.
Fiscal Year 2024 Outlook
Post management affirmed its outlook for fiscal year 2024 Adjusted EBITDA of $1,370-$1,390 million.

Guidance

Post Holdings Affirms FY24 Adjusted EBITDA Outlook Of $1.37B-$1.39B

<ul>
<li>The paper re-iterates the significant&nbsp;anti-fibrotic effect of Aramchol 300mg BID in patients with metabolic dysfunction associated steatohepatitis (MASH)</li>
<li>Data is confirmed using 3 objective measurements; NASH&nbsp;CRN, paired ranked reading, and Artificial Intelligence (AI) quantitative digital analysis</li>
<li>Continuous&nbsp;histological fibrosis scores generated in antifibrotic trials by digital pathology images analysis (DIA) quantify antifibrotic effects with greater sensitivity and larger dynamic range than Conventional Pathology</li>
</ul>
TEL AVIV, Israel, Sept. 25, 2024 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibro-inflammatory diseases announced today that the one-year results of the Open-Label part (ARCON ) of its global Phase 3 trial of Aramchol in 150 patients with NASH and fibrosis (ARMOR) have been published in&nbsp;<a href="https://journals.lww.com/hep/abstract/9900/aramchol_improves_hepatic_fibrosis_in_metabolic.930.aspx">Hepatology</a>.&nbsp;

Biotech

General

GLMD

Galmed 1-Year Results Of The Open-Label Part Of Its Global Phase 3 Trial Of Aramchol In 150 Patients With NASH And Fibrosis Have Been Published In Hepatology

WIIM

KB Home shares are trading lower following Q3 earnings. While EPS and revenues beat estimates, the company said net orders were flat with last year and it saw softening in late June through July.

SEEL

Seelos Therapeutics shares are trading higher. The company announced a 1-for-16 reverse stock split.

Seelos Therapeutics, Inc. (Nasdaq:&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4262814-1&amp;h=1790813364&amp;u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fseelos-therapeutics-announces-1-for-8-reverse-stock-split-302144966.html%23financial-modal&amp;a=SEEL">SEEL</a>) ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that its Board of Directors approved a 1-for-16 reverse stock split of its outstanding shares of common stock, to be effective as of&nbsp;12:01 a.m. Eastern Time on Friday, September 27, 2024.
The Company's common stock, par value $0.001, will begin trading on a reverse stock split-adjusted basis at the opening of the market on&nbsp;Friday, September 27, 2024. Following the reverse stock split, the Company's common stock will continue to trade on the Nasdaq Capital Market under the symbol "SEEL" with the new CUSIP number, 81577F 406. The reverse stock split is intended for the Company to regain compliance with the minimum bid price requirement of&nbsp;$1.00&nbsp;per share of common stock for continued listing on the Nasdaq Capital Market. The reverse stock split was approved by the Company's Board of Directors pursuant to Section 78.207 of the Nevada Revised Statutes and was effectuated by the filing of a Certificate of Change with office of the Nevada Secretary of State.

Stock Split

Seelos Therapeutics Announces 1-For-16 Reverse Stock Split, Will Begin Trading On A Reverse Stock Split-Adjusted Basis At The Opening Of The Market On Friday, September 27, 2024

Believes Pacira's Cash Balance of $400 million, Roughly 59% of its Market Capitalization, is Grossly Inefficient.
Emphasizes the Current Stock Price Offers an Extraordinary Opportunity to Create Meaningful Return for Shareholders
MIAMI, Sept. 25, 2024 /PRNewswire/ --&nbsp;DOMA Perpetual Capital Management LLC today sent a letter to the Board of Directors of Pacira Biosciences (NYSE:&nbsp;PCRX) urging the Board to accelerate and increase its stock repurchase.&nbsp;
 &nbsp;

Dividends

Buybacks

Management

PCRX

DOMA Perpetual Sends Letter To Board of Directors Of Pacira Biosciences To Immediately Accelerate And Increase Its Share Buyback Program To Enhance Return To Shareholders; Believes Pacira's Cash Balance Of $400M, Roughly 59% of its Market Capitalization, is Grossly Inefficient

Maxim Group analyst Jason McCarthy maintains Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Buy and raises the price target from $12 to $25.

Price Target

Analyst Ratings

CAPR

Maxim Group Maintains Buy on Capricor Therapeutics, Raises Price Target to $25

Chinese e-commerce juggernaut Alibaba Group Holding&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) flagship annual Apsara Conference became an essential platform for the country&#8217;s AI start-ups to showcase their accomplishments and more.
Now in its 16th year, the Apsara Conference was estimated to attract more than 280 companies and an audience of over 90,000, SCMP <a target="_blank" href="https://www.scmp.com/tech/big-tech/article/3279773/how-alibaba-has-become-enabler-chinas-ai-industry-through-its-apsara-conference" rel="noreferrer noopener">cited</a> Liu Jie, Hangzhou&#8217;s communist party secretary.
The event reflects Alibaba&#8217;s initiatives to accomplish its AI ambitions despite the U.S. advanced technology sanctions, which have restricted its access to sophisticated Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) AI chips.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/24/09/41004045/whats-going-on-with-chinese-stocks-alibaba-nio-xpeng-li-auto-on-tuesday" rel="noreferrer noopener">Alibaba and Chinese Tech Stocks Surge After Central Bank Eases Lending Requirements</a>
Alibaba remains aggressively invested in its self-developed Tongyi Qianwen LLM family and has emerged as an investor in all four of China&#8217;s &#8220;AI tigers&#8221;—Moonshot AI, Baichuan AI,&nbsp;Zhipu AI, and&nbsp;MiniMax.
Moonshot AI set up a booth at the Apsara exhibition area to showcase its Kimi AI chatbot. The 01.AI start-up founded by computer scientist&nbsp;Lee Kai-fu bagged Alibaba&#8217;s help. Motiff, a Beijing-based start-up, emerged as a first-time participant at the Apsara Conference this year.
Alibaba Cloud revealed several case studies showcasing its role in AI empowerment, including a partnership with electric vehicle maker XPeng Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) to enhance the smart cockpit experience.
Apsara also allowed foreign companies like Nvidia to showcase their offerings for China&#8217;s AI industry.
<a target="_blank" href="https://www.benzinga.com/government/24/09/40977069/alibaba-teams-up-with-nvidia-to-supercharge-evs-for-chinese-automakers-report" rel="noreferrer noopener">Earlier this week</a>, Alibaba tapped Nvidia to boost the&nbsp;autonomous driving&nbsp;experience for Chinese smart vehicle owners like&nbsp;Li Auto Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LI#NYSE">LI</a>).
Alibaba, considered the tech barometer for China, has increased over 11% in the last 12 months as the U.S. and China key rate cuts posed tailwinds for the economies. Investors can gain exposure to Alibaba through the Goldman Sachs Hedge Industry VIP ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GVIP#NYSE">GVIP</a>) and the JPMorgan U.S. Tech Leaders ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JTEK#NASDAQ">JTEK</a>).
Price Action: BABA stock closed higher by 7.88% at $97.19 on Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/government/24/09/40923879/chinas-ymtc-makes-strides-in-chip-production-substitutes-asml-lam-research-tech-as-us-sanctions-bite" target="_blank" rel="noreferrer noopener">China&#8217;s YMTC Makes Strides in Chip Production; Substitutes ASML, Lam Research Tech As US Sanctions Bite: Report</a></li>
</ul>
Photo by Ascannio via Shutterstock

Government

Regulations

Emerging Markets

Tech

Media

BABA

GVIP

JTEK

NVDA

XPEV

Nvidia, XPeng Join Alibaba's Apsara Conference to Showcase AI Tech Advancements

If you've been watching the housing market lately, you've probably noticed that things have gotten pretty complicated even for people with a lot of money. According to an analysis by The Wall Street Journal, more high-earning households are choosing to rent instead of buying a home.&nbsp;
Between 2018 and 2022, the percentage of households earning over $750,000 a year who rent rose to 10.5%, the highest since the mid-2000s. But why are millionaires opting to rent when they could buy?
Don't Miss:
<ul>
<li>A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> you can become part of the next big real estate boom today.</a></li>
<li>This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, and you only need $100</a>.</li>
</ul>
The reasons behind this trend are pretty straightforward. Home prices have skyrocketed to the point where even people making three-quarters of a million dollars a year are finding it tough to justify buying. Mortgage rates have doubled since 2022, making homeownership more expensive than ever.&nbsp;
So, many are asking themselves, &#8220;Wow, I have all this money and I can&#8217;t find a house,&#8221; and &#8220;<a href="https://www.benzinga.com/general/entrepreneurship/24/03/37944606/should-you-rent-or-buy-a-house">Why buy when renting is cheaper?</a>&#8220;
See Also: Rory McIlroy&#8217;s mansion in Florida is worth $22 million today, doubling from 2017 —<a href="https://benzinga.com/money/rory-mcilroys-florida-mansion-doubled-in-value"> here&#8217;s how to get started investing in real estate with just $100</a>
Take George Goognin, a millionaire fintech founder. He moved to the U.S. to buy a home, first in Silicon Valley, then Miami and finally New York. After months of searching and seeing nothing he liked, he rented a luxury three-bedroom apartment in Manhattan for $19,000 a month. He's part of a growing group of high-income earners choosing to rent.
This change is the result of several important factors. First, decent properties are limited and fairly priced even for those with millions to spend. Even for the wealthy, purchasing becomes less appealing financially due to <a href="https://www.benzinga.com/real-estate/24/06/39294393/kevin-oleary-warns-high-mortgage-rates-are-here-to-stay-says-housing-costs-have-gone-up-30-40-percen">high mortgage rates</a>. <a href="https://www.benzinga.com/personal-finance/24/09/40834365/from-cars-and-clothes-to-caskets-renting-is-the-new-normal-for-personal-finance">Renting provides convenience and flexibility</a>, as there is no long-term commitment and no need to worry about upkeep or fluctuations in the market.
Trending: Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a>
Furthermore, some people would rather invest in stocks or other assets than a house, particularly if they don&#8217;t think property values will rise considerably.
It's not just George Goognin. A recent study showed that between 2018 and 2022, the share of renters among households with net worths in the top 5% nearly doubled. That's a significant shift from the past when homeownership was the ultimate goal.
Trending: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/connect-invest-real-estate-notes">These high-yield real estate notes that pay 7.5% &#8211; 9% make earning passive income easier than ever.</a>
Kris Mullins, Capital Max&#8217;s Chief Marketing Officer, believes that <a href="https://www.benzinga.com/real-estate/24/07/39662917/2024s-hottest-investment-despite-housing-crisis-experts-explain-why-rental-properties-will-make-you">increasing demand makes rental homes a desirable investment</a> because Gen Z and millennials are delaying homeownership or avoiding it altogether, favoring the freedom that renting provides.&nbsp;
Mullins told GoBankingRates, &#8220;With a growing renter pool chasing a potentially limited supply of rental units, vacancy rates are likely to stay low, which translates to consistent rental income for property investors.&#8221;
See Also: These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a>
<a href="https://www.benzinga.com/real-estate/24/06/39293984/grant-cardone-says-owning-rental-properties-will-pay-big-dividends-as-u-s-rents-hit-highest-levels-s">Real estate mogul Grant Cardone agrees</a> with this sentiment. He added, &#8220;baby boomers will trade homeownership for rentals, tapping their equity for travel, investing and later for assisted living.&#8221;&nbsp;
Cardone recommends that individual investors take advantage of the increasing demand for rentals, pointing out that in 50 of the largest cities, renting costs about half as much as owning a home, making rental properties a great investment opportunity.
Read Next:
<ul>
<li>This billion-dollar fund has invested in the next big real estate boom,<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> here's how you can join for $10.</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends<a href="https://www.benzinga.com/money/arrived-private-credit-fund"> would you invest in it</a>?</li>
</ul>

Real Estate

'Wow, I Have All This Money And I Can't Find A House' – 10.5% Of Households With Annual Incomes Of More Than $750,000 Now Rent

ORCL

Oracle Files For Four-part Notes Offering; Size Not Disclosed

AIMD

Ainos shares are trading higher after the company announced it has received Institutional Review Board approval from the National Taiwan University Hospital for its clinical trial focused on treating oral warts in HIV-positive patients.

RMNI

Rimini Street Ordered To Pay Oracle $58.5M In Attorneys' Fees And Costs By Oct 23 Following District Court Ruling; Rimini Files Notice Of Appeal Against The Award

Northland Capital Markets analyst Mike Grondahl initiates coverage on Cipher Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) with a Outperform rating and announces Price Target of $6.

Initiation

CIFR

Northland Capital Markets Initiates Coverage On Cipher Mining with Outperform Rating, Announces Price Target of $6

Bill Maher, host of Real Time with Bill Maher, has voiced his strong criticism of cryptocurrency, calling it a major threat to the environment due to its <a href="https://www.benzinga.com/markets/cryptocurrency/24/02/36954312/power-hungry-bitcoin-and-other-cryptos-drained-as-much-power-with-mining-as-whole-of-austr">excessive energy consumption</a>.
What Happened: During an <a href="https://x.com/billmaher/status/1838646493118632340">episode</a>, Maher pointed out that the energy usage associated with Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) mining is undoing much of the progress being made in green energy initiatives.
&#8220;All the progress that we&#8217;re making with green energy is being sucked away by crypto,&#8221; Maher remarked, noting that the industry consumes an estimated 8% of the world's electricity. 
Maher highlighted the absurdity of cryptocurrency mining, describing it as &#8220;nonsense of finding a number,&#8221; and drew a stark comparison between crypto&#8217;s energy impact and the environmental cost of traditional fossil fuels.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41014040/from-ceo-to-inmate-caroline-ellison-sentenced-to-24-months-in-ftx-case-what-the-industry-m">From CEO To Inmate: Caroline Ellison Sentenced To 24 Months In FTX Case—What The Industry Must Learn</a>
&#8220;It&#8217;s comparable to putting 15.7 million additional gas-powered cars on the road,&#8221; Maher said, criticizing the environmental burden that crypto imposes.
Maher&#8217;s comments come as the debate around cryptocurrency's carbon footprint intensifies. 
<a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41006505/bitcoin-mining-stock-cipher-mining-is-climbing-today-whats-going-on">Bitcoin mining</a>, in particular, has faced scrutiny for its reliance on energy-intensive proof-of-work protocols, which require vast data centers and computational power to validate transactions.
What&#8217;s Next: As the conversation on crypto's environmental footprint heats up, experts and industry leaders will likely tackle these issues at the upcoming Benzinga <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41012993/sec-charges-trusttoken-and-truecoin-with-fraud-and-unregistered-securities-offering-in-sta">SEC Charges TrustToken And TrueCoin With Fraud And Unregistered Securities Offering In Stablecoin Case</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bill Maher Slams Bitcoin Mining: 'Nonsense Of Finding A Number' Means Green Energy Progress Is Being 'Sucked Away By Crypto'

WINT

Windtree Therapeutics Reports Topline Results From Phase 2B SEISMiC Extension Study Of Istaroxime In Early Cardiogenic Shock; Istaroxime Significantly Improves Systolic Blood Pressure Over Six Hours And Shows Notable Secondary Endpoint Improvements

– Post-hoc analysis from pivotal Phase 3 REST-ON trial confirmed the efficacy of LUMRYZ in study participants who were and were not using a stable dose of an alerting agent – &nbsp;
– Baseline data underscore that alerting agents alone are often insufficient&nbsp;for excessive daytime sleepiness –
DUBLIN, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDL#NASDAQ">AVDL</a>), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication of results of a post-hoc analysis from the completed pivotal Phase 3 REST-ON clinical trial. Results demonstrated clinically significant improvements from baseline in wakefulness, overall condition, number of weekly cataplexy episodes, and excessive daytime sleepiness in patients taking LUMRYZ (sodium oxybate) compared to those taking placebo, regardless of concomitant use of alerting agents. The paper, titled "Efficacy of Once-Nightly Sodium Oxybate (FT218) on Daytime Symptoms in Individuals With Narcolepsy With or Without Concomitant Alerting Agent Use: A Post Hoc Analysis From the Phase 3 REST-ON Trial," was published online in <a href="https://www.globenewswire.com/Tracker?data=D9x_8rgnhYOtZIShD2JH65LSU2y_BhURrcJc8Z2ub7Mxzilo6nPlz3cU4yXI9e4AE8sP7miFPl8XWuRbw3gB96ivPtAkn94dMyhQ5s8UQojFFP4MGlX1QRKaRuI9f5sddYl8dhNuX2sdGneP37414uH2hMOCPoqbohxB8A-nDLU=">Sleep Medicine</a>.

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

Avadel Pharmaceuticals Announces Publication Of Data In 'Sleep Medicine' Highlighting Efficacy Of LUMRYZ Extended-Release Oral Suspension In Improving Narcolepsy Symptoms Regardless Of Concomitant Use Of An Alerting Agent

Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor &nbsp;
Erasca is also evaluating naporafenib plus trametinib in the ongoing SEACRAFT-2 pivotal Phase 3 trial in NRAS-mutant melanoma where favorable survival was previously demonstrated in pooled analyses
Erasca to host virtual R&amp;D update for investors on Thursday, October 24, 2024, at 8:30 AM ET
SAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERAS#NASDAQ">ERAS</a>), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced an oral presentation of preliminary SEACRAFT-1 Phase 1 data for naporafenib plus trametinib (MEKINIST&#xAE;) in patients with locally advanced unresectable or metastatic solid tumor malignancies with RAS Q61X mutations at the 36th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics taking place October 23-25 in Barcelona, Spain. Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor.
Erasca plans to host a virtual investor event to provide a research and development (R&amp;D) update on naporafenib and the RAS targeting franchise on Thursday, October 24, 2024, at 8:30 AM ET in conjunction with the 36th ENA Symposium. A live question and answer session will follow the formal presentation. To register for the event, please click <a href="https://www.globenewswire.com/Tracker?data=4mp2ewsOVezFaoAOBTsostdEy2QWJFnWODvsuPIqh0xCqiMWXd4H7oMfMRDvejotpK72CcQRzWPymGDQW5pG-ehklZu2qHjZJrYcrasLwT0=">here.</a>

ERAS

Erasca To Present Preliminary SEACRAFT-1 Phase 1 Data For Naporafenib Plus Trametinib In RAS Q61X Mutant Solid Tumors As Oral Presentation At 36th EORTC-NCI-AACR Symposium

Ainos Receives IRB Approval From National Taiwan University Hospital For HIV-Oral Warts Clinical Trial, Showcasing FDA-Designated Orphan Drug VELDONA; Awaits Taiwan FDA Approval To Begin

– Completion of nonclinical safety and toxicity studies, Phase 1 clinical trial design and established Maximum Recommended Starting Dose
– Completion of pre- Clinical Trial Application (CTA) meeting with Health Canada
– Submission of the CTA for the Phase 1 clinical study of Normal Healthy Volunteers and ulcerative colitis patients
– On track towards clinical site initiation and dosing of first patient in Phase 1 human clinical study before year end &nbsp;
Carlsbad,&nbsp;CA, Sept. 25, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=gPj0tOryZ-1XW_E6RFBEORtv60JdxuEIbv9aJRkFLlwRvmgHOPjp-ojKtMhXtHHVu196onCrTJfCqDvtSXAlvaX_MKdoNecJoT85HqMnBD0=">Palisade Bio, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) ("Palisade," "Palisade Bio" or the "Company"), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today provided an update on its progress toward the launch of its Phase 1 human clinical study for PALI-2108 for the treatment of ulcerative colitis (UC).
The Company's lead program, PALI-2108, is a locally activated PDE4 inhibitor prodrug in development for treating patients with moderate to severely active UC. Leveraging advanced machine learning, the Company's research has identified a measurable threshold of elevated PDE4B expression across more than 1,600 patients and 10 studies, identifying over-expressing patients in over 70% of cases. This finding supports the potential for an FDA-approved test that uses PDE4B expression as a reliable marker for patient enrichment. The Company believes this will lead to better UC patient selection, thereby increasing the efficacy of Palisade's PDE4-inhibiting prodrug therapeutic. Additionally, the Company is advancing a second approach featuring six PDE4-related biomarkers, which has demonstrated superior performance compared to benchmark tests and is specifically tailored for PDE4 inhibition, providing a targeted solution to improve therapeutic outcomes. The integration of PCR-based assays aimed at potential FDA approval will ensure precision in patient targeting. These developments underscore the Company's commitment to leading the field of precision medicine for UC, advancing personalized treatment strategies that promise to transform patient care.

PALI

Palisade Bio Provides Update On Progress Toward Launch Of Phase 1 Human Clinical Study For Lead Program, PALI-2108 For The Treatment Of Ulcerative Colitis; On Track Towards Clinical Site Initiation And Dosing Of First Patient In Phase 1 Human Clinical Study Before Year End

Cipher Pharmaceuticals (CPHRF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Justin Keywo...

Cipher Pharmaceuticals: Hold Rating Justified by High Valuation and Uncertain M&A Outcomes

Cipher Pharmaceuticals (TSE:CPH) has released an update. Cipher Pharmaceuticals Inc. successfully conducted its annual and special meeting, where s...

Cipher Pharmaceuticals Shareholders Approve All Resolutions

Cipher Pharmaceuticals acquires dermatology products from ParaPRO

Cipher Pharmaceuticals (TSE:CPH) has released an update. Cipher Pharmaceuticals has expanded its portfolio with the acquisition of Natroba&#x2122;, a high...

Cipher Pharmaceuticals Buys Dermatology Brand for $89.5M

In a report released today, Justin Keywood from Stifel Nicolaus maintained a Hold rating on Cipher Pharmaceuticals (CPHRF – Research Report), with ...

Stifel Nicolaus Sticks to Their Hold Rating for Cipher Pharmaceuticals (CPHRF)

Cipher Pharmaceuticals (TSE:CPH) has released an update. Cipher Pharmaceuticals Inc. has announced the release of its Q2 2024 financial results aft...

Cipher Pharmaceuticals Announces Q2 2024 Earnings Call

Cipher Pharmaceuticals (TSE:CPH) has released an update. Cipher Pharmaceuticals has sustained its financial performance in Q2 2024 with an adjusted...

Cipher Pharmaceuticals Maintains Solid Q2 Performance

Cipher Pharmaceuticals GAAP EPS of $0.12, revenue of $5.3M

Cipher Pharmaceuticals (TSE:CPH) has released an update. Cipher Pharmaceuticals reports that its partner Moberg Pharma AB has observed lower than e...

Cipher Pharma Reports Moberg's Study Setback

Stifel Nicolaus analyst Justin Keywood maintained a Buy rating on Cipher Pharmaceuticals (CPHRF – Research Report) today and set a price target of ...

Stifel Nicolaus Sticks to Its Buy Rating for Cipher Pharmaceuticals (CPHRF)

Will Uplisting Be the Catalyst to Send Shares of this Pharma Company Higher?

Small Cap

Press Releases

Cipher Pharmaceuticals Schedules Q4 2023 Earnings Release and Conference Call

Earnings

Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results

Cipher Pharmaceuticals Schedules Q1 2024 Earnings Release and Conference Call

Cipher Pharmaceuticals Reports First Quarter 2024 Results

Cipher Pharmaceuticals Announces Results of Annual and Special Meeting of Shareholders

Cipher Pharmaceuticals Acquires Profitable Growth Dermatology Products from ParaPRO for US$89.5 Million

Cipher Pharmaceuticals Schedules Q2 2024 Earnings Release and Conference Call

Cipher Pharmaceuticals Reports Second Quarter 2024 Results

Cipher Pharmaceuticals Partner Moberg Pharma AB Provides Update on MOB-015 Phase 3 Study

TSX:CPH

Cipher Pharmaceuticals

Stifel

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

Cipher Pharmaceuticals

Cipher Pharmaceuticals (CPHRF) Forecast

Cipher Pharmaceuticals (OTC:CPHRF) Stock, Quote.Headers.trade-ideas